Skip to main content
SpringerLink
Log in

Carence en fer et prise en charge dans les MICI

Iron deficiency and management in the inflammatory bowel diseases

  • Technique / Technique
  • Published:
Côlon & Rectum

Résumé

L’anémie par carence en fer est fréquente dans les maladies inflammatoires chroniques intestinales et impacte la qualité de vie. Elle doit être dépistée et être corrigée. La supplémentation intraveineuse est privilégiée à la voie orale pour sa meilleure efficacité et sa tolérance. En fonction de la dose nécessaire, Venofer ou Ferinject peuvent être prescrits avec des performances meilleures pour le Ferinject en termes de rapidité de correction et de dose perfusée. La récidive doit être dépistée et traitée pour une meilleure qualité de vie des patients.

Abstract

Iron deficiency anemia is common in inflammatory bowel diseases and impairs quality of life. It should be detected and corrected. Efficacy and tolerance of intravenous iron supplementation is better than oral. Depending on quantity, Venofer or Ferinject could be administered but Ferinject allowed quicker correction and higher concentration. Iron deficiency anemia recurrence should be detected and treated to improve quality of life of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Dignass AU, Gasche C, Bettenworth D, et al (2015) European Crohn’s and Colitis Organisation [ECCO]. (2015). European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 9:211–22

    Article  PubMed  Google Scholar 

  2. Erichsen K, Ulvik RJ, Nysaeter G, et al (2005) Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 40:1058–65

    Article  CAS  PubMed  Google Scholar 

  3. Schroder O, Mickisch O, Seidler U, et al (2005) Intravenous iron sucrose vs. oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 100:2503–9

    Article  PubMed  Google Scholar 

  4. Bonovas S, Fiorino G, Allocca M, et al (2016) Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) 95:5

    Article  Google Scholar 

  5. Evstatiev R, Marteau P, Iqbal T, et al (2011) FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 141:846–53

    Article  CAS  PubMed  Google Scholar 

  6. Reinisch W, Staun M, Tandon RK, et al (2013) A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 108:1877–88

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département de pathologies digestives, institut mutualiste Montsouris, 42 boulevard Jourdan, F-75014, Paris, France

    M. Simon

Authors
  1. M. Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Simon.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Simon, M. Carence en fer et prise en charge dans les MICI. Colon Rectum 10, 125–127 (2016). https://doi.org/10.1007/s11725-016-0643-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11725-016-0643-5

Mots clés

Keywords

Search

Navigation